Paper Details

  1. Home
  2. Paper Details

A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

Author: CharneyD, CramerJ, FrismanL, FyeC, HendersonW, RosenheckR, ThomasJ, XuW

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Overview

Clozapine is a widely used antipsychotic drug for patients with refractory schizophrenia, with a low risk of extrapyramidal side effects but potential for agranulocytosis. Long-term effects on symptoms, social functioning, healthcare utilization, and cost need further investigation.
Paper Details　
Original Abstract of the Article :
Clozapine, a relatively expensive antipsychotic drug, is widely used to treat patients with refractory schizophrenia. It has a low incidence of extrapyramidal side effects but may cause agranulocytosis. There have been no long-term assessments of its effect on symptoms, social functioning, and the u...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJM199709183371202

データ提供：米国国立医学図書館（NLM）

Clozapine vs. Haloperidol: A Battle for Refractory Schizophrenia

Schizophrenia is a complex mental illness that can be challenging to treat. This study examines the effectiveness of two antipsychotic medications, clozapine and haloperidol, in patients with refractory schizophrenia, a form of the illness that is resistant to standard treatments. The researchers compared the effects of these medications on symptoms, social functioning, and the use and cost of healthcare, providing valuable insights into the management of refractory schizophrenia.

Clozapine: A Promising Option for Refractory Schizophrenia

The study found that clozapine, a relatively expensive antipsychotic drug, demonstrated promising results in treating patients with refractory schizophrenia. While clozapine can cause agranulocytosis, a potentially serious side effect, the study found that it had a lower incidence of extrapyramidal side effects compared to haloperidol. These findings suggest that clozapine may be a valuable option for patients with refractory schizophrenia, but careful monitoring for potential side effects is crucial.

Navigating the Challenges of Refractory Schizophrenia

This study highlights the need for effective treatments for patients with refractory schizophrenia, a condition that can be difficult to manage. The findings suggest that clozapine may offer a promising alternative for these patients, but careful consideration of the potential risks and benefits is essential. It's like navigating a challenging desert landscape, where finding the right path can lead to improved outcomes and a better quality of life for those struggling with this complex illness.

Dr. Camel's Conclusion

This study underscores the importance of finding the right treatment strategies for patients with refractory schizophrenia. It's like searching for a hidden oasis in a vast and unforgiving desert, where the right combination of knowledge, experience, and compassion can lead to positive outcomes. We must continue to explore new treatment options and develop strategies that offer hope and relief to those living with this challenging illness.

Date :
  1. Date Completed 1997-09-18
  2. Date Revised 2022-03-11
Further Info :

Pubmed ID

9295240

DOI: Digital Object Identifier

10.1056/NEJM199709183371202

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.